Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 09:04 ET | Source: SNS Insider pvt ltd

Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS Insider

Austin, United States, June 18, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, The Ophthalmic Clinical Trials Market size was valued at USD 1.75 Billion in 2025 and is expected to reach USD...
June 11, 2026 04:00 ET | Source: Oculis Holding AG

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to...
April 07, 2026 04:00 ET | Source: Oculis Holding AG

Oculis to Participate in Upcoming Investor Conferences

ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
February 17, 2026 04:00 ET | Source: Oculis Holding AG

Oculis Appoints Katie Kazem as Chief Legal Officer

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief...
November 19, 2025 08:56 ET | Source: Research and Markets

Blepharitis Market Analysis and Forecast Report 2025-2035 Featuring Tarsus Pharmaceuticals, Valeant Pharmaceuticals, Azura Ophthalmics, and Attillaps Pharmaceuticals

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Blepharitis Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added...
July 28, 2025 09:46 ET | Source: Research and Markets

Dry Eye Disease Treatment Market Insights, Competitive Landscape, and Forecast Report 2024-2032 | Artificial Tears Dominate the Market, Offering Immediate Symptom Relief

Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Dry Eye Disease Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to ResearchAndMarkets.com's offering. ...
May 08, 2025 16:05 ET | Source: Oculis Holding AG

Oculis Reports Q1 2025 Financial Results and Provides Company Update

The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high...
May 07, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Present at Upcoming May Investor Conferences

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and...
May 01, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and...
April 01, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...